T. Rowe Price Associates
INZY

T. Rowe Price Associates’s Inozyme Pharma INZY Stock Holding History

T. Rowe Price Associates’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-19,533
Closed -$18K – 3099
2025
Q1 		$18K Hold
19,533
– – ﹤0.01% 3009
2024
Q4 		$55K Buy
19,533
+2,930
+18% +$11.1K ﹤0.01% 2927
2024
Q3 		$87K Buy
16,603
+233
+1% +$1.21K ﹤0.01% 2846
2024
Q2 		$74K Buy
16,370
+2,148
+15% +$10.4K ﹤0.01% 2795
2024
Q1 		$109K Buy
14,222
+1,526
+12% +$8.37K ﹤0.01% 2766
2023
Q4 		$55K Buy
+12,696
New +$45.1K ﹤0.01% 2797

Other funds holding INZY

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return

T. Rowe Price Associates's INZY Position: Q2 2025 in Review

T. Rowe Price Associates sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 19,533 shares — an estimated $18K sold.

T. Rowe Price Associates first reported a position in INZY in Q4 2023 and held it in 6 quarters. The position peaked at $109K in Q1 2024. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

  • T. Rowe Price Associates reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
  • T. Rowe Price Associates sold 19,533 Inozyme Pharma shares in Q2 2025, an estimated $18K.
  • T. Rowe Price Associates first reported a position in Inozyme Pharma in Q4 2023 and held it in 6 quarters.
  • T. Rowe Price Associates's Inozyme Pharma position peaked at $109K in Q1 2024.
  • 86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on T. Rowe Price Associates's 13F filing for Q2 2025, filed 14 Aug 2025.